Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled: IP protection 09/29/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 314
Posts 40,454
Boards Moderated 35
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
XenaLives Member Level  Sunday, 09/29/19 11:57:20 AM
Re: None
Post # of 231002 
Compiled: IP protection 09/29/19
___________________________________________________________________________________

Pain Patent (from georgejjl)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151086364

Investor 2014 links to a list of patents with Alexandre Vamvakides dating back to 2008 gives an idea:
https://patents.justia.com/inventor/alexandre-vamvakides

Patent update re: AV1066.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149346961

AVXL patent on AI to treat Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169367

IP.....good article on Intellectual Property in the BioPharma sector
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150118360

Greenspam3 links to new patent applications for visceral and neuropathic pain and also regulation of blood pressure:

https://patentscope.wipo.int/search/en/detail.jsf?docId=US243292967&recNum=1&office&queryString=FP%3A%28anavex%29&prevFilter&sortOption=Pub+Date+Desc&maxRec=38&fbclid=IwAR0iQoR01ea7s1UHVBUfMZG9_2CFKNXSiBIZHsMoQ7R7qQBMIbF_crtkokE

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019108653&tab=PCTBIBLIO&office&prevFilter&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&recNum=2&maxRec=38&fbclid=IwAR1R-6LmOI1qaWSmh1gixjbLF6qLMAuhqT2mS-DT173ea-5uiJId_DNz6iA

Beginning of discussion for above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149304398

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, is pleased to announce that it has been issued U.S. Patent No. 8,673,931 (the “Patent”). The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer’s disease (AD), type 2 diabetes and insulin resistance. (posted by georgejjl)
https://www.anavex.com/anavex-awarded-new-u-s-patent/

United States Patent Application January 24, 2019
NEURODEVELOPMENTAL DISORDER THERAPY
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148757220

Patent filing released 04/25/19: Anavex 2-73 for the Treatment of Cardiac Dysfunction
(from TTTav66)
https://patentscope.wipo.int/search/de/detail.jsf?docId=US241444653
Discussion here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148457849
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148470928

Patent - ANAVEX2-73 in a method of treatment for neurodevelopmental disorders:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148472474

AV1066 for pain an approved patent which is "ready for issue" as of 12/28/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145909839

Patent for specific crystaline forms of 2-73 provides extended IP protection:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145420021

Patent for Insomnia: (EN) A2-73 AS A THERAPEUIC FOR INSOMNIA, ANXIETY, AND AGITATION
Abstract:
(EN)A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30mg. (from basparks79)
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=173B4DDABFF25B0C26F75F5B8E98D703.wapp2nA?docId=WO2018022848&recNum=1&maxRec=13&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&tab=PCT+Biblio

More on the patent for Insomnia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144833903
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144834373
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144842204

Anavex, Cognision, and Ariana are doing ground breaking research in Alzheimer's disease:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145774113

December 20, 2018 Anavex & Cognision U.S. Patent Application, intermittent dosage :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145735301
more info on Cognision in the partners post

The following posts relate to the above patent:
Tool suite used in the above patent (thanks Nidan7500):
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
https://www.advancedbrainmonitoring.com/

Summary of Checci patent Application:
https://investorshub.advfn.com/boards/read_msg.aspx?

ERP patent app with related organizations:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147781853
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147668300
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147844189
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271

Additional info in Anavex partners post linked at the bottom of the primary post.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist